PP50. INVESTIGATION THE ASSOCIATION BETWEEN HUMAN HERPESVIRUS (HSV) 1, 2, 6 , 7 POSITIVE AND TLR9 GENE POLYMORPHISM IN THE PROSTATE CANCER
EBRU ETEM1, Yasemin Bulut2, Nusret Akpolat3, Ebru Korkmaz2, Hüseyin Yüce1, Mehmet Yapar4. 1. Firat University, Medical Faculty, Department of Medical Biology and Genetic, ELAZIG. 2. Firat University, Medical Faculty, Department of Microbiology and Clinical Microbiology, ELAZIG. 3. Firat University, Medical Faculty, Department of Pathology, ELAZIG. 4. Gulhane Military Medical Academy, Deparment of Virology, ANKARA. e-mail: ebruetem@gmail.com
*Corresponding Author:
page: 70

Abstract

Objective: The secretion of type 1 IFN in response to herpes simplex virus type 1 (HSV-1) and 2  in vitro is mediated by TLR9. In this study, we purpose whether the any association between TLR9 1635G/A poymorphisms and HSV1,2,6,7 positivity and the incidence of HSV1,2,6,7 are positively linked to infection in the prostate tissue samples.

Material and methods:  The DNA was extracted from the parraffin embedded tissues. Four different HSV DNA detection were done by polymerase chain reaction (PCR). Genotyping of TLR9 1635 G/A polymorphism was performed by PCR-Restriction Fragment Lenght Polymorphism (PCR-RFLP).  Fischer's test was used for statistical analysis.

Results: HSV DNA positive was detected in 12 of 21 (57.1%) prostate cancer (PCa), in 15 of 24 (62.5%)  prostatic intraepithelial neoplasia (PIN) and in 14 of 21 (66.7%) benign prostatic hyperplasia (BPH), all of total 66 samples. Differences in TLR9 1635A/G allelic frequencies were not statistically observed, neither between PCa, PIN and BPH nor between HSV-positive and HSV-negative all samples.

 

HSV1  HSV2 HSV6 HSV7
Pca (21) 7 (33.3%) 7 (33.3%) 3 (14.3%) 2 (9.5%)
PIN (24) 4 (16.7%) 7 (29.2%) 4 (16.7%) 6 (25%)
BPH (21) 2 (9.5%) 7 (33.3%) 6 (28.6%) 2 (9.5%)
Total  13      21     13 10

 

Discussion: Our findings indicate that it was not found statiscially significant association between  HSV1,2,6,7 and TLR9 1635 G/A polymorphism. As result, we consider that future investigations are needed to provided conclusive evidence on the role of these pathogen and gene in the prostate cancer.




Number 20
VOL. 20 (1), 2017
Number 19
VOL. 19 (2), 2016
Number 19
VOL. 19 (1), 2016
Number 18
VOL. 18 (2), 2015
Number 18
VOL. 18 (1), 2015
Number 17
VOL. 17 (2), 2014
Number 17
VOL. 17 (1), 2014
Number 16
VOL. 16 (2), 2013
Number 16
VOL. 16 (1), 2013
Number 15
VOL. 15 (2), 2012
Number 15
VOL. 15, 2012 Supplement
Number 15
Vol. 15 (1), 2012
Number 14
14 - Vol. 14 (2), 2011
Number 14
The 9th Balkan Congress of Medical Genetics
Number 14
14 - Vol. 14 (1), 2011
Number 13
Vol. 13 (2), 2010
Number 13
Vol.13 (1), 2010
Number 12
Vol.12 (2), 2009
Number 12
Vol.12 (1), 2009
Number 11
Vol.11 (2),2008
Number 11
Vol.11 (1),2008
Number 10
Vol.10 (2), 2007
Number 10
10 (1),2007
Number 9
1&2, 2006
Number 9
3&4, 2006
Number 8
1&2, 2005
Number 8
3&4, 2004
Number 7
1&2, 2004
Number 6
3&4, 2003
Number 6
1&2, 2003
Number 5
3&4, 2002
Number 5
1&2, 2002
Number 4
Vol.3 (4), 2000
Number 4
Vol.2 (4), 1999
Number 4
Vol.1 (4), 1998
Number 4
3&4, 2001
Number 4
1&2, 2001
Number 3
Vol.3 (3), 2000
Number 3
Vol.2 (3), 1999
Number 3
Vol.1 (3), 1998
Number 2
Vol.3(2), 2000
Number 2
Vol.1 (2), 1998
Number 2
Vol.2 (2), 1999
Number 1
Vol.3 (1), 2000
Number 1
Vol.2 (1), 1999
Number 1
Vol.1 (1), 1998

 

 


 About the journal ::: Editorial ::: Subscription ::: Information for authors ::: Contact
 Copyright © Balkan Journal of Medical Genetics 2006